SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (1952)10/1/1997 12:57:00 AM
From: carl w. trygstad   of 6136
 
As an old time viral geneticist, the way you make resistant mutants is to start with a large culture. As a country doc, patients take drugs that are easy to take and don't make them sick. As a former NIH research associate, I am biased into thinking the idea hit them hard with lots of drugs before they are too sick to take the drugs or the viral load is too high or mutates makes sense. As one who knows how research is done vs the street, I would expect the trial results to be better than the clinic results and that no one drug will have all the best features. As an observer, I suspect there will be several good PIs but the marked share will go to the one that works and is easiest to take or costs the least. As an investor, I bought AGPH near the low yesterday.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News